Squarepoint’s Palvella Therapeutics PVLA Stock Holding History

Squarepoint’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.63M	Buy	+13,067	New	+$1.36M	﹤0.01%	2360
2024 Q2	–	Sell	-1,823	Closed	-$26.7K	–	4761
2024 Q1	$26.7K	Buy	+1,823	New	+$25.4K	﹤0.01%	3911
2021 Q4	–	Sell	-445	Closed	-$184K	–	3593
2021 Q3	$184K	Sell	445 -1,175	-73%	-$409K	﹤0.01%	2526
2021 Q2	$496K	Buy	+1,620	New	+$355K	﹤0.01%	2134
2020 Q4	–	Sell	-218	Closed	-$36K	–	3320
2020 Q3	$36K	Buy	+218	New	+$49.6K	﹤0.01%	2395
2020 Q2	–	Sell	-1,022	Closed	-$186K	–	2565
2020 Q1	$186K	Buy	1,022 +462	+83%	+$116K	﹤0.01%	1499
2019 Q4	$162K	Buy	+560	New	+$155K	﹤0.01%	2268
2019 Q3	–	Sell	-135	Closed	-$51K	–	2728
2019 Q2	$51K	Buy	+135	New	+$40.3K	﹤0.01%	2280
2018 Q3	–	Sell	-354	Closed	-$143K	–	2268
2018 Q2	$143K	Buy	354 +126	+55%	+$60K	﹤0.01%	1596
2018 Q1	$124K	Sell	228 -438	-66%	-$271K	﹤0.01%	1556
2017 Q4	$402K	Buy	+666	New	+$310K	0.01%	1327

Other funds holding PVLA

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Squarepoint's PVLA Position: Q1 2026 in Review

Squarepoint opened a new position in Palvella Therapeutics (PVLA) in Q1 2026: 13,067 shares worth $1.63M. The stake represents ﹤0.01% of the portfolio and ranks #2360 among its holdings. This is a return to the name: Squarepoint previously reported a position in PVLA as recently as Q1 2024.

Squarepoint first reported a position in PVLA in Q4 2017 and has held it in 11 quarters since. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

Squarepoint held 13,067 shares of Palvella Therapeutics worth $1.63M as of Q1 2026.
Palvella Therapeutics was a new Squarepoint position in Q1 2026.
Palvella Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2360 holding.
Squarepoint first reported a position in Palvella Therapeutics in Q4 2017 and has held it in 11 quarters since.
180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.